 |
|
|||
 |
||||
23 July 2004 - 21:00
EuropaBio appoints new board members; names Jack Huttner, Genencor's Vice President of Communications and Public Affairs, to the association.Feike Sijbesma, Chairman of EuropaBio, the European Biotechnology industry association announced that Mr. Jack Huttner (1), Dr Bernward Garthoff (2), Mr Tom Saylor (3) and Mr. Odd Magne Rødseth (4) have been appointed to the EuropaBio main Board. Jack Huttner is Vice President of Corporate Communications and Public Affairs, Genencor International, Inc and Dr Bernward Garthoff is Member of the Board of Management of Bayer CropScience AG. Tom Saylor is Chief Executive, Arecor. and represents the BIA, the UK BioIndustry Association on the EuropaBio board while Odd Magne Rødseth is CEO Aqua Gen AS and Chairman of the Norwegian Biotechnology Association. These appointments bring elected Board members of EuropaBio to a total of twenty-one (5) representing large and small biotech companies based throughout Europe. Speaking on the appointments Feike Sijbesma said "These board members representing the full range of biotech sectors as well as large and small companies alike will strengthen EuropaBio's capacity to contribute to the European policy agenda on biotechnology and life sciences." EuropaBio, the European Association for Bioindustries, has 35 corporate members operating worldwide and 24 national biotechnology associations representing some 1500 small and medium sized enterprises involved in research and development, testing, manufacturing and distribution of biotechnology products. http://www.europabio.org For further information, contact Adeline Farrelly
(1) Mr. Jack Huttner, Vice President of Corporate Communications and Public Affairs, Genencor International, Inc Jack Huttner has global responsibility for corporate communications, government, trade and public relations for Genencor International - one of the largest biotechnology companies in the world with the European headquarters in Leiden, the Netherlands. The company operates three manufacturing plants in Europe: two in Finland and one in Belgium. Huttner was the founding Executive Director of the New York Biotechnology Association, Inc., (NYBA) founder of the New York State Biotech association and has served on a number of boards and commissions including those of the New York Academies of Medicine and Science and the Councils for Biotechnology at Stony Brook and Cornell Universities. Currently, Huttner serves on the Biomass Technical Advisory Committee formed by an Act of the U.S. Congress to oversee the federal government's $250 million bio-energy R&D budget. He is chairman of the Industrial and Environmental governing board of the Biotechnology Industry Organization (BIO) in Washington, DC and has been active in EuropaBio for several years. He also represents industry at an OECD advisory committee for biotechnology and sustainable development. About Genencor (2) Dr. Bernward Garthoff, Member of the Board of Management of Bayer Crop Science AG Dr. Bernward Garthoff is a member of the Board of Management and responsible for Technology at the Bayer CropScience AG. Bernward Garthoff studied veterinary medicine at Hannover University and joined Bayer in 1976 where he held a variety of functions in pharmacological research. Returning to Germany, after a period in the US as Senior Vice President for Research and Development at Bayer's then U.S. pharmaceuticals subsidiary, Miles, Dr Garthoff become Head of the Institute for Cardiovascular and Arteriosclerosis Research. He moved to the Crop Protection Business Group in 1994, becoming Head of Portfolio Management in April of that year. He has recently managed the integration process entrained by the acquisition of Aventis CropScience. About Bayer CropScience (3) Mr. Tom Saylor, CEO, Arecor Ltd and representative of the UK BioIndustry Association Tom Saylor is CEO of Arecor Limited, a company focused upon advanced drug delivery systems for parenterals. Tom has extensive experience in building and managing entrepreneurial organizations and negotiating commercial agreements. Previously, he was CEO of Sirus, a drug targeting and delivery company based in Cambridge, England. Prior to joining Sirus, Tom was Chairman and founder of Lotus Healthcare Corporation, an Asian-based integrated pharmaceutical company. Tom built Lotus Healthcare from a small marketing group into a leading producer and marketer of analgesics, cardiovascular and GI products with two GMP manufacturing sites and a sales staff of 100 representatives covering the top 35 cities of China. Tom was also Chief Executive Officer of Cell Systems Limited, a company focusing on medical applications of cryopreservation and algal biotechnology. Previously, Tom was Executive Vice President of a multi-billion dollar diversified industrial and financial group based in New York and a prinicipal negotiator in the Tokyo Round of multilateral trade negotiations. About Arecor (4) Mr. Odd Magne Rødseth, CEO, Aqua Gen AS and Chairman of the Norwegian Bioindustry Association Odd Magne Rødseth is CEO of Aqua Gen AS - which is Norway's premier producer of eyed ova from Atlantic salmon and rainbow trout. Mr. Rødseth has a Master's Degree in Microbiology from the University of Bergen. He is a former researcher at the University of Bergen and the Institute of Marine Research (IMR) where his main research topics where fish immunology and developing vaccines for the aquaculture industry where he was part of the "Frisk Fisk" programme that was at the basis of the first vaccine against cold water vibriosis. For the last ten years he has been Research Director of the Dutch pharmaceutical company Intervet International in charge of developing new fish vaccines. About Aqua Gen
MEMBERS
|
|
Top
Print
Mail a colleague about this page